Premium
Comparison of the Serum and Intracellular Pharmacokinetics of Azithromycin in Healthy and Diabetic Volunteers
Author(s) -
Ernst Erika J.,
Klepser Michael E.,
Klepser Teresa B.,
Nightingale Charles H.,
Hunsicker Lawrence G.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.7.657.35176
Subject(s) - azithromycin , pharmacokinetics , medicine , diabetes mellitus , pharmacology , serum concentration , intracellular , endocrinology , antibiotics , chemistry , biology , microbiology and biotechnology , biochemistry
Study Objective . To compare serum and intracellular pharmacokinetics of azithromycin in healthy volunteers and patients with diabetes. Design . Open‐label, parallel study. Setting . Clinical research center. Subjects . Twelve patients with diabetes and 12 healthy volunteers. Interventions . Subjects were given a single 500‐mg dose of azithromycin followed by 250 mg/day for 2 days. Blood samples were obtained just before and after the third dose for up to 24 hours for serum and 168 hours for intracellular measurement of azithromycin. Measurements and Main Results . Pharmacokinetic parameters were calculated by noncompartmental methods and compared with a t test. The groups did not differ in maximum concentration, time to maximum concentration, or area under the concentration‐time curve in serum or polymorphonuclear cells (PMNs). Differences in the PMN:serum ratio were observed at the 24‐hour time point (healthy 1209 ± 432, diabetic 859 ± 286, p= 0.051). Conclusion . In general, the pharmacokinetics of azithromycin are comparable in diabetics and healthy volunteers. Accumulation of drug in macrophages was slightly lower in patients.